vs
Side-by-side financial comparison of Invivyd, Inc. (IVVD) and NextPlat Corp (NXPL). Click either name above to swap in a different company.
Invivyd, Inc. is the larger business by last-quarter revenue ($17.2M vs $12.8M, roughly 1.3× NextPlat Corp). NextPlat Corp runs the higher net margin — -40.2% vs -64.3%, a 24.1% gap on every dollar of revenue. On growth, Invivyd, Inc. posted the faster year-over-year revenue change (24.5% vs -21.1%).
Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.
IVVD vs NXPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.2M | $12.8M |
| Net Profit | $-11.1M | $-5.1M |
| Gross Margin | — | 14.3% |
| Operating Margin | -73.0% | -28.9% |
| Net Margin | -64.3% | -40.2% |
| Revenue YoY | 24.5% | -21.1% |
| Net Profit YoY | 40.0% | -70.6% |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.2M | $12.8M | ||
| Q3 25 | $13.1M | $13.8M | ||
| Q2 25 | $11.8M | $13.2M | ||
| Q1 25 | $11.3M | $14.5M | ||
| Q4 24 | $13.8M | $16.2M | ||
| Q3 24 | $9.3M | $15.4M | ||
| Q2 24 | $2.3M | $17.0M | ||
| Q1 24 | $0 | $17.5M |
| Q4 25 | $-11.1M | $-5.1M | ||
| Q3 25 | $-10.5M | $-2.2M | ||
| Q2 25 | $-14.7M | $-1.8M | ||
| Q1 25 | $-16.3M | $-1.3M | ||
| Q4 24 | $-18.4M | $-3.0M | ||
| Q3 24 | $-60.7M | $-4.2M | ||
| Q2 24 | $-47.2M | $-5.3M | ||
| Q1 24 | $-43.5M | $-1.5M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | 19.9% | ||
| Q2 25 | — | 21.8% | ||
| Q1 25 | — | 23.8% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | — | 23.2% | ||
| Q2 24 | — | 34.5% | ||
| Q1 24 | — | 27.8% |
| Q4 25 | -73.0% | -28.9% | ||
| Q3 25 | -84.0% | -14.5% | ||
| Q2 25 | -127.8% | -13.8% | ||
| Q1 25 | -149.7% | -10.2% | ||
| Q4 24 | -139.1% | -14.1% | ||
| Q3 24 | -670.0% | -52.1% | ||
| Q2 24 | -2175.2% | -64.1% | ||
| Q1 24 | — | -10.5% |
| Q4 25 | -64.3% | -40.2% | ||
| Q3 25 | -79.7% | -15.9% | ||
| Q2 25 | -124.4% | -13.5% | ||
| Q1 25 | -144.1% | -9.2% | ||
| Q4 24 | -133.5% | -18.6% | ||
| Q3 24 | -653.1% | -27.4% | ||
| Q2 24 | -2086.9% | -31.3% | ||
| Q1 24 | — | -8.5% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $-0.06 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $-0.14 | $-0.05 | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.51 | $-0.22 | ||
| Q2 24 | $-0.40 | — | ||
| Q1 24 | $-0.38 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $226.7M | $13.7M |
| Total DebtLower is stronger | — | $1.3M |
| Stockholders' EquityBook value | $241.5M | $17.3M |
| Total Assets | $276.9M | $27.5M |
| Debt / EquityLower = less leverage | — | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $226.7M | $13.7M | ||
| Q3 25 | $85.0M | $13.9M | ||
| Q2 25 | $34.9M | $16.6M | ||
| Q1 25 | $48.1M | $17.7M | ||
| Q4 24 | $69.3M | $20.0M | ||
| Q3 24 | $106.9M | $20.4M | ||
| Q2 24 | $147.9M | $24.9M | ||
| Q1 24 | $189.4M | $23.5M |
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $1.4M |
| Q4 25 | $241.5M | $17.3M | ||
| Q3 25 | $93.1M | $21.4M | ||
| Q2 25 | $42.8M | $23.5M | ||
| Q1 25 | $54.1M | $25.3M | ||
| Q4 24 | $67.5M | $27.3M | ||
| Q3 24 | $83.2M | $22.5M | ||
| Q2 24 | $140.6M | $26.5M | ||
| Q1 24 | $178.5M | $31.2M |
| Q4 25 | $276.9M | $27.5M | ||
| Q3 25 | $139.2M | $30.0M | ||
| Q2 25 | $89.1M | $31.0M | ||
| Q1 25 | $103.7M | $35.2M | ||
| Q4 24 | $129.5M | $37.1M | ||
| Q3 24 | $161.9M | $41.1M | ||
| Q2 24 | $177.3M | $51.5M | ||
| Q1 24 | $215.5M | $65.1M |
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.05× | ||
| Q2 25 | — | 0.05× | ||
| Q1 25 | — | 0.05× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.05× | ||
| Q1 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.5M | $-302.0K |
| Free Cash FlowOCF − Capex | — | $-339.0K |
| FCF MarginFCF / Revenue | — | -2.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.5M | $-302.0K | ||
| Q3 25 | $-8.3M | $-2.7M | ||
| Q2 25 | $-13.3M | $-1.0M | ||
| Q1 25 | $-21.1M | $-2.1M | ||
| Q4 24 | $-37.6M | $-476.0K | ||
| Q3 24 | $-41.1M | $-4.6M | ||
| Q2 24 | $-41.6M | $2.3M | ||
| Q1 24 | $-50.2M | $-2.7M |
| Q4 25 | — | $-339.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | $-13.3M | $-1.1M | ||
| Q1 25 | $-21.3M | $-2.1M | ||
| Q4 24 | $-37.6M | $-508.0K | ||
| Q3 24 | $-41.1M | $-4.7M | ||
| Q2 24 | — | $2.2M | ||
| Q1 24 | $-50.4M | $-2.7M |
| Q4 25 | — | -2.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | -112.9% | -8.0% | ||
| Q1 25 | -188.2% | -14.3% | ||
| Q4 24 | -272.2% | -3.1% | ||
| Q3 24 | -441.6% | -30.6% | ||
| Q2 24 | — | 13.2% | ||
| Q1 24 | — | -15.7% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.1% | 0.1% | ||
| Q1 25 | 1.3% | 0.2% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | — | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IVVD
Segment breakdown not available.
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
